Page last updated: 2024-10-28

hexamethonium and ADDH

hexamethonium has been researched along with ADDH in 1 studies

Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ueno, K1
Togashi, H1
Matsumoto, M1
Ohashi, S1
Saito, H1
Yoshioka, M1

Other Studies

1 other study available for hexamethonium and ADDH

ArticleYear
Alpha4beta2 nicotinic acetylcholine receptor activation ameliorates impairment of spontaneous alternation behavior in stroke-prone spontaneously hypertensive rats, an animal model of attention deficit hyperactivity disorder.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 302, Issue:1

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Attention Deficit Disorder with Hyperactivity; Beh

2002